Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5514-5520

  Grossi, Peter M ^a   Ochiai, Hidenobu ^a   Archer, Gary E ^a   McLendon, Roger E ^a   Zalutsky, Michael R ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Bigner, Darell D ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MACROMOLECULE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RAT; TIGHT JUNCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; INFUSIONS, PARENTERAL; NEOPLASM METASTASIS; RATS; RATS, NUDE; SURVIVAL ANALYSIS;

EID: 0344758982     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Markesbery, W. R., Brooks, W. H., Gupta, G. D., and Young, A. B. Treatment for patients with cerebral metastases. Arch. Neurol., 35: 754-756, 1978.
2. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994.
3. Leavens, M. E., Moser, R. P., Obbens, E. A. and Iwata, K. I. Surgical treatment of metastatic brain tumors. Cancer Bull., 38: 39-42, 1986.
4. Baselga, J. Clinical trials of single-agent trastuzumab (Herceptin). Semin. Oncol., 27: 20-26, 2000.
5. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
6. Day, E. D., Lassiter, S., Woodhall, B., Mahaley, J. L., and Mahaley, M. S., Jr. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res., 25: 773-778, 1965.
7. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res., 49: 2807-2813, 1989.
8. Pestalozzi, B. C., and Brignoli, S. Trastuzumab in CSF. J. Clin. Oncol., 18: 2349-2351, 2000.
9. Pegram, M., and Slamon, D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin. Oncol., 27: 13-19, 2000.
10. Bigner, D. D., Brown, M. T., Friedman, A. H., Coleman, R. E., Akabani, G., Friedman, H. S., Thorstad, W. L., McLendon, R. E., Bigner, S. H., Zhao, X. G., Pegram, C. N., Wikstrand, C. J., Herndon, J. E., 2nd, Vick, N. A., Paleologos, N., Cokgor, I., Provenzale, J. M., and Zalutsky, M. R. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J. Clin. Oncol., 16: 2202-2212, 1998.
11. Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., and Oldfield, E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 91: 2076-2080, 1994.
12. Heimberger, A. B., Archer, G. E., McLendon, R. E., Hulette, C., Friedman, A. H., Friedman, H. S., Bigner, D. D., and Sampson, J. H. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res., 6: 4148-4153, 2000.
13. Laske, D. W., Youle, R. J., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.
14. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1993.
15. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
16. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res., 50: 814s-819s, 1990.
17. Zimm, S., Wampler, G. L., Stablein, D., Hazra, T., and Young, H. F. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer (Phila.), 48: 384-394, 1981.
18. Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., and Oldfield, E. H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg., 82: 1021-1029, 1995.
19. Morrison, P. F., Laske, D. W., Bobo, H., Oldfield, E. H., and Dedrick, R. L. High-flow microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol., 266: R292-R305, 1994.
20. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
21. Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., and Slamon, D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 17: 2235-2249, 1998.
22. Riva, P., Franceschi, G., Arista, A., Frattarelli, M., Riva, N., Cremonini, A. M., Giuliani, G., and Casi, M. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer (Phila.), 80: 2733-2742, 1997.
23. Sampson, J. H., Crotty, L. E., Lee, S., Archer, G. E., Ashley, D. M., Wikstrand, C. J., Hale, L. P., Small, C., Dranoff, G., Friedman, A. H., Friedman, H. S. and Bigner, D. D. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. USA, 97: 7503-7508, 2000.